Latest Kidney Cancer News
Kidney Cancer News elsewhere on the Web
David Braun, MD, PhD discusses the selection of immune checkpoint inhibitor use in clear cell renal cell carcinoma
Nivolumab plus ipilimumab may generate positive long-term outcomes in patients with advanced renal cell carcinoma regardless of IMDC risk status.
Collecting and analyzing patient data through an AI tool may help with more accurately predicting outcomes and personalizing treatment.
Data from CheckMate 214 show a steady improvement in overall survival with nivolumab/ipilimumab in patients with favorable-risk disease.
Get the latest updates on cancer waiting times in England, and what it means for people with cancer, from Cancer Research UK
Key opinion leaders examine the Phase II PAPMET clinical trial, focusing on its design and progression-free survival outcomes.
The key opinion leaders examine the data from the KEYNOTE-426 trial, focusing on safety and efficacy outcomes along with other pertinent updates.
Renal cell carcinoma specialists provide a comprehensive overview of chromophobe renal cell carcinoma (ChRCC), including its definition, background, and distinctive characteristics.
Brian I. Rini, MD, FASCO, on findings from a biomarker analysis of the KEYNOTE-426 trial of pembrolizumab/axitinib vs sunitinib in renal cell carcinoma.
The Food and Drug Administration granted a fast track designation to ADI-270, an off-the-shelf CAR-T cell therapy for clear cell renal cell carcinoma.
No results found.
Articles from Kidney Cancer UK
No results found.
No results found.